- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02128087
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders (RATA)
2017년 4월 12일 업데이트: Sebastian Linnemayr, RAND
In this project the investigators develop and test a short message service (SMS) intervention based on the Information Motivation and Behavior skills (IMB) model.
Reminding Adolescents To Adhere (RATA) prompts youths at two clinics in Uganda to take their medications and offers social support via weekly text messages.
The investigators propose to adapt their previous successful SMS-intervention to the specific needs of youths and to evaluate the relative effectiveness of one-way versus two-way text messages (where two-way messages allow youths to respond to messages and we hypothesize that this may increase perceived social support that may be important for youth populations).
We will also test the effectiveness of SMS messages over the longer-term (2 years), for which currently no information is available.
연구 개요
상세 설명
The primary goal of the proposed study is to develop and test SMS-based text messages for improving medication adherence among HIV-positive youths in a resource-limited setting.
The study will be conducted in three phases: Phase 1 will consist of qualitative interviews with patients, clinic providers and directors, and community leaders and will elicit information on barriers to treatment and adherence patterns and cognitive obstacles to adherence that may be addressed by RATA.
A second focus of this phase will be to investigate the familiarity with and attitude towards SMS messages among adolescents, and their attitudes towards different aspects of these messages.
Parameters of the messages that will be probed include their frequency, content, and form using Figure 1 as a guiding principle for this exploratory phase.
Phase 2 will use the findings from Phase 1 to develop and implement RATA in a randomized controlled trial (RCT).
A sample of 330 clients aged 15-24 who are in HIV care and show signs of problems with adherence will be recruited and randomized into one of three equal-sized intervention arms: a control group that will receive usual care, or one of two treatment groups in which participants will receive usual care and additionally will receive either two-way SMS messages or one-way SMS messages.
All RATA participants will be followed for two years.
Assessments will be conducted at baseline and every 6 months over the course of 24 months.
Medication event monitoring system (MEMS)-caps measured medication adherence will be the primary outcome measure, while viral load (for a subset of clients) CD4 count, self-reported adherence and pharmacy refill data as well as retention in care constitute secondary outcomes.
Phase 3 will be used to analyze the collected data, conduct qualitative interviews with providers, clinic administrators, and study participants to learn about implementation difficulties and areas of improvement, and to share preliminary results and project implementation insights with these key players.
This stage allows evaluating the feasibility and sustainability of the intervention for potential scale-up, for which we will also conduct a relative cost-effectiveness analysis of two- versus one-way messages.
RATA will be extended to the control group in Year 5 if findings from phase 2 suggest its success at improving outcomes.
연구 유형
중재적
등록 (예상)
330
단계
- 해당 없음
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
15년 (어린이, 성인)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- age 15-24
- have been in HIV care at the clinic for at least three months
- are currently taking HIV-related medication (ART or co-trimoxazole)
- have demonstrated adherence problems (defined as having missed at least one medication dose per week on average)
- either own a phone or have regular access to one
- intend to stay at the clinic for the study period
- are not in boarding school (where phones are forbidden)
Exclusion Criteria:
- does not speak or understand either English or Luganda
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 건강 서비스 연구
- 할당: 무작위
- 중재 모델: 요인 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
간섭 없음: Control group
This study arm will receive care as usual.
|
|
|
실험적: Two-way SMS intervention group
Two-way messages allow the recipient of the SMS message (the patient) to respond to the messages ("We hope you are feeling well today.
Reply 1 if well, 2 if unwell") to request a follow-up call from the clinic.
|
Clients will receive a weekly two-way SMS, meaning that the clients in this group will receive the same message as in the one-way SMS study arm, but in addition will be asked how they feel.
Clients are required to either press 1 or respond "well" or press 2 or write 'Unwell" in response in the language of their choice within 48 hours.
A missing response after 48 hours triggers a second SMS to remind the client to respond.
If after 24 more hours the participant still does not respond or if at any point s/he responds "unwell" then the study coordinator will follow up with a call within 24 hours.
|
|
실험적: One-way SMS intervention group
Clients will receive a weekly one-way SMS with the message "We hope you are feeling well today."
There will be no prompt for response.
|
Clients will receive a weekly one-way SMS message.
There will be no prompt for any response.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Medication adherence rates using electronically monitored adherence (MEMS cap) data
기간: 6 months after enrollment
|
Medication Event Monitoring System (MEMS)-cap data will be collected continuously over the course of the 24-month study period allowing us to investigate daily adherence and its timing.
MEMS caps data indicating the date and time when the participant opened their pill bottle (either one of the ART medications or prophylaxis if not on ART yet) will be used to calculate the primary outcome variable of adherence (# of actual bottle openings / # of prescribed bottle openings).
|
6 months after enrollment
|
|
Medication adherence rates using electronically monitored adherence (MEMS cap) data
기간: 12 months after enrollment
|
Medication Event Monitoring System (MEMS)-cap data will be collected continuously over the course of the 24-month study period allowing us to investigate daily adherence and its timing.
MEMS caps data indicating the date and time when the participant opened their pill bottle (either one of the ART medications or prophylaxis if not on ART yet) will be used to calculate the primary outcome variable of adherence (# of actual bottle openings / # of prescribed bottle openings).
|
12 months after enrollment
|
|
Medication adherence rates using electronically monitored adherence (MEMS cap) data
기간: 24 months after enrollment
|
Medication Event Monitoring System (MEMS)-cap data will be collected continuously over the course of the 24-month study period allowing us to investigate daily adherence and its timing.
MEMS caps data indicating the date and time when the participant opened their pill bottle (either one of the ART medications or prophylaxis if not on ART yet) will be used to calculate the primary outcome variable of adherence (# of actual bottle openings / # of prescribed bottle openings).
|
24 months after enrollment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Fraction of clients displaying adherence of 90% or more
기간: At 6, 12, 18 and 24 months
|
MEMS caps data indicating the date and time when the participant opened their pill bottle (either one of the ART medications or prophylaxis if not on ART yet) will be used to calculate the secondary outcome measures of fraction of clients displaying adherence of 90% or more.
|
At 6, 12, 18 and 24 months
|
|
Indicator for treatment interruptions of more than 48 hours
기간: At 6, 12, 18 and 24 months
|
MEMS caps data indicating the date and time when the participant opened their pill bottle (either one of the ART medications or prophylaxis if not on ART yet) will be used to calculate the secondary outcome measures of an indicator for treatment interruptions of more than 48 hours.
|
At 6, 12, 18 and 24 months
|
|
Viral load assays
기간: At month 12
|
A randomized subset of 30 clients from each intervention arm (90 total) will measure viral load assays at month 12.
|
At month 12
|
|
Self-reported adherence
기간: At baseline, 6, 12, 18 and 24 months
|
We will ask about number of missed doses over the past 7 days.
Adherence is calculated as a proportion of prescribed doses taken.
|
At baseline, 6, 12, 18 and 24 months
|
|
Pharmacy Refill Adherence
기간: Months 6, 12, 18 and 24
|
All patients on ART receive their medications in 30-day supplies from the Infectious Disease Institute (IDI) and Mildmay clinic pharmacies.
For clients on co-trimoxazole, the drugs are typically dispensed in units of 90 count.
We will adjust the measure according to the refill period specific to each client.
A composite continuous multiple interval measure of medication availability or refill rate will be calculated (# of pills dispensed/ # pills prescribed per day)/ days between refills.
|
Months 6, 12, 18 and 24
|
|
Clinic Attendance
기간: Continuous over 24 months
|
Attendance at regularly scheduled clinic visits as part of usual care will be tracked for all participants from the electronic client database and will be available in real-time to the study coordinator.
|
Continuous over 24 months
|
|
Cluster of differentiation 4 (CD4) count
기간: Occasionally over 24 months
|
CD4 counts will be chart abstracted from the clinic data; they are typically taken about every six months
|
Occasionally over 24 months
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2013년 2월 1일
기본 완료 (실제)
2016년 1월 31일
연구 완료 (실제)
2017년 3월 31일
연구 등록 날짜
최초 제출
2014년 4월 15일
QC 기준을 충족하는 최초 제출
2014년 4월 29일
처음 게시됨 (추정)
2014년 5월 1일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2017년 4월 14일
QC 기준을 충족하는 마지막 업데이트 제출
2017년 4월 12일
마지막으로 확인됨
2017년 4월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 1R01HD074925-01 (미국 NIH 보조금/계약)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .